International perspectives on the development, application, and evaluation of a multicancer early detection strategy

Johnson, Sonali; Zurn, Shalini Jayasekar; Anderson, Benjamin O.; Vetter, Beatrice; Katz, Zachary; Milner, Danny A.

doi:10.1002/cncr.33927

Cited by 7 publications

(14 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, both can be maximally investigated and clinically employed to provide more personalized preventative strategies and therapy for individuals and populations [ 25 ]. Recent works discussing liquid biopsies with breast cancer, genomic sequencing with cervical cancer, and multi-cancer early detection (MCED) demonstrate PPM’s potential [ 8 , 16 , 42 - 50 ].…”

Section: Reviewmentioning

confidence: 99%

See 1 more Smart Citation

An Overview of the Use of Precision Population Medicine in Cancer Care: First of a Series

Yang¹,

Nittala²,

Velazquez³

et al. 2023

Cureus

View full text Add to dashboard Cite

Advances in science and technology in the past century and a half have helped improve disease management, prevention, and early diagnosis and better health maintenance. These have led to a longer life expectancy in most developed and middle-income countries. However, resource- and infrastructure-scarce countries and populations have not enjoyed these benefits. Furthermore, in every society, including in developed nations, the lag time from new advances, either in the laboratory or from clinical trials, to using those findings in day-to-day medical practice often takes many years and sometimes close to or longer than a decade. A similar trend is seen in the application of “precision medicine” (PM) in terms of improving population health (PH). One of the reasons for such lack of application of precision medicine in population health is the misunderstanding of equating precision medicine with genomic medicine (GM) as if they are the same. Precision medicine needs to be recognized as encompassing genomic medicine in addition to other new developments such as big data analytics, electronic health records (EHR), telemedicine, and information communication technology. By leveraging these new developments together and applying well-tested epidemiological concepts, it can be posited that population/public health can be improved. In this paper, we take cancer as an example of the benefits of recognizing the potential of precision medicine in applying it to population/public health. Breast cancer and cervical cancer are taken as examples to demonstrate these hypotheses. There exists significant evidence already to show the importance of recognizing “precision population medicine” (PPM) in improving cancer outcomes not only in individual patients but also for its applications in early detection and cancer screening (especially in high-risk populations) and achieving those goals in a more cost-efficient manner that can reach resource- and infrastructure-scarce societies and populations. This is the first report of a series that will focus on individual cancer sites in the future.

show abstract

Section: Reviewmentioning

confidence: 99%

“…Representing another application of PPM, MCED employs free circulating DNA to detect cancers, especially those that lack guideline screening [ 46 , 48 - 50 ]. This tool considers the frequency of cancer types, stage/grade, and symptomatic versus asymptomatic factors toward developing trends.…”

Section: Reviewmentioning

confidence: 99%

An Overview of the Use of Precision Population Medicine in Cancer Care: First of a Series

Yang¹,

Nittala²,

Velazquez³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Because the design and delivery of cancer-screening programs across global regions are markedly different, the emphasis of this article is from the US perspective, with discussion of key topics related to other low-middle-high-income countries addressed in the companion international perspectives commentary. 17 Broadly speaking, screening of asymptomatic average-risk adults is recommended for cancers of high incidence, by tests proven to reduce mortality from those cancers. Although a detailed review of each disease and screening modality is beyond our present scope, an overview is provided to highlight common themes on the successes and substantial challenges of the status quo.…”

Section: Current Statusmentioning

confidence: 99%

“…Before assessing the opportunities and barriers to clinical research on multicancer testing, the current state of cancer screening should be considered. Because the design and delivery of cancer‐screening programs across global regions are markedly different, the emphasis of this article is from the US perspective, with discussion of key topics related to other low‐middle‐high–income countries addressed in the companion international perspectives commentary 17 . Broadly speaking, screening of asymptomatic average‐risk adults is recommended for cancers of high incidence, by tests proven to reduce mortality from those cancers.…”

Section: Current Statusmentioning

confidence: 99%

Multicancer early detection test: Preclinical, translational, and clinical evidence–generation plan and provocative questions

Kisiel

Papadopoulos

Liu

et al. 2022

Cancer

View full text Add to dashboard Cite

Minimally invasive molecular biomarkers have been applied to the early detection of multiple cancers in large scale case‐control and cohort studies. These demonstrations of feasibility herald the potential for permanent transformation of current cancer screening paradigms. This commentary discusses the major opportunities and challenges facing the preclinical development and clinical validation of multicancer early detection test strategies. From a diverse set of early detection research perspectives, the authors recommend specific approaches and highlight important questions for future investigation.

show abstract

“…Furthermore, decision makers and health systems should plan now to allocate human and financial resources to deploy MCED to these populations. As also discussed in the commentary on international perspectives within this supplement, in low‐income and middle‐income countries in particular, it will be critical to understand how misperceptions and stigmas about screening and diagnosis of cancers may influence health‐related beliefs and practices 55 . Addressing stigmas and misinformation in these populations is critical to developing an effective education strategy for MCED in some countries and cultures.…”

Section: Opportunities and Challengesmentioning

confidence: 99%

Patient engagement and advocacy considerations in development and implementation of a multicancer early detection program

Schear

Hoyos

Davis

et al. 2022

Cancer

View full text Add to dashboard Cite

BRIEF BACKGROUNDCollaboration with organizations that advocate for patients with cancer is a critical step in actively partnering with patients and embedding patient engagement in cancer-related research and practice across the cancer care continuum. As novel and potentially highly disruptive technologies are developed, like multicancer early detection (MCED)-bloodbased screening tests designed to identify the presence of more than 1 cancer-advocacy organizations are poised to ensure that patients' needs and preferences inform the development, planning, and implementation of these technologies. MCED diverges from traditional organ-based cancer screening in that it aims to detect any malignant changes throughout the body, providing for an initial screening for cancer in which positive tests would be followed by more focused diagnostic testing. Development of this approach to cancer screening, supported by sound epidemiologic and biologic reasoning, has been vigorously pursued by academic and industry scientists, and emerging performance data are promising. 1 This commentary, specific to patient engagement and advocacy considerations, is 1 of several commentaries included in this special issue of Cancer born out of a Universal Cancer Screening Summit (the Summit) hosted by the Mayo Clinic Cancer Center, the American Cancer Society, and the Union for International Cancer Control in February of 2020. The Summit was the first convening of advocacy and nongovernmental organizations (outside of the private industry developing MCED technology) to shape a global MCED strategy. Each commentary emerged from a key theme discussed at the Summit and addresses a unique aspect of MCED, including: preclinical/clinical research, regulatory approval, advocacy and patient perspectives, international considerations, clinical practice guidelines, modeling analyses to estimate health and economic outcomes, and industry engagement. These commentaries collectively offer the first frameworks for the development, validation, and clinical application, as well as advocacy, related to MCED technologies. The current commentary emerged from discussions of the critical importance of engaging patients in cancer research and development of new screening, diagnosis, and treatment technologies.The goal of this commentary is to begin a conversation about how the delivery of MCED may affect patients and communities, examining 4 domains of access to care 2,3 : acceptance, access, affordability, and accountability. We also summarize patient perspectives regarding existing screening modalities and share initial patient insights about the concept of MCED as an example of how powerful patient partnerships can be in designing health systems and services. The primary objective of this commentary is to bring visibility to the importance of including the patient voice at all stages in the development and implementation of MCED technologies.

show abstract

International perspectives on the development, application, and evaluation of a multicancer early detection strategy

Cited by 7 publications

References 24 publications

An Overview of the Use of Precision Population Medicine in Cancer Care: First of a Series

An Overview of the Use of Precision Population Medicine in Cancer Care: First of a Series

Multicancer early detection test: Preclinical, translational, and clinical evidence–generation plan and provocative questions

Patient engagement and advocacy considerations in development and implementation of a multicancer early detection program

Contact Info

Product

Resources

About